Stockscreener 앱 받기
6.04
9.58%
-0.64
시간 외 거래:
6.13
0.09
+1.49%
Agenus Inc 주식(AGEN)의 최신 뉴스
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference - BioSpace
Agenus Inc. (AGEN) options chain - Yahoo Finance UK
Agenus Inc. (AGEN) stock price, news, quote and history - Yahoo Finance Singapore
Agenus Inc. (AGEN) interactive stock chart – Yahoo Finance - Yahoo Finance Singapore
Agenus Gets Armenia Approval for Botensilimab-Balstilimab Combination - Yahoo Finance
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer - Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - 뉴스와이어
Agenus (AGEN) Reports Durable 3-Year Ovarian Cancer Trial Results Amid Valuation and Financial Challenges - GuruFocus
Agenus Inc. (AGEN) latest stock news and headlines - Yahoo Finance UK
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Yahoo Finance
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026 - BioSpace
Director Wright acquires 1.18K units of future Agenus (AGEN) shares at $6.893 each. - Stock Titan
A director acquires 4,443 Agenus (AGEN) shares through an election to receive fees in stock. - Stock Titan
Joe Cotton’s Stock Pick of the Week: A risky biotech stock, Agenus, a promising colorectal cancer drug - NKyTribune
Agenus: Pivot To Neoadjuvant Setting In CRC Sends Stock SoaringBut Caution Advised - Seeking Alpha
Agenus: Hot Times As It Trudges Towards BOT/BAL Submission (NASDAQ:AGEN) - Seeking Alpha
Agenus Shares Rise After Chardan Initiates Coverage at Buy - marketscreener.com
AGEN Initiates Coverage On Agenus by Rodman & Renshaw -- Rating Buy - GuruFocus
Rodman & Renshaw initiates Agenus stock with buy on cancer therapy - Investing.com Nigeria
Rodman & Renshaw initiates Agenus stock with buy on cancer therapy - Investing.com
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last? - easternprogress.com
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Dura - The National Law Review
Agenus Stock Price Forecast. Should You Buy AGEN? - StockInvest.us
New Agenus (AGEN) director receives 7,500 stock options - Stock Titan
Spouse-held shares feature in Agenus (AGEN) director's stake - Stock Titan
September Stakeholder Webcast on ROBBIN Phase 3 and Neoadjuvant ImmunotherapyAgenus - Oncodaily
Agenus Inc Share PriceAGEN, RNS News, Articles, Quotes, & Charts (NASDAQ:AGEN) - Proactive financial news
AGEN S-3 FilingsAgenus Inc. SEC S-3 - stocktitan.net
Agenus Inc. (AGEN) Shareholder/Analyst CallSlideshow (NASDAQ:AGEN) 2026-09-11 - Seeking Alpha
BOT+BAL: Three-Year Overall Survival Data in Recurrent Ovarian Cancer – Agenus - Oncodaily
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - BioSpace
Agenus to Present 3-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Oncodaily
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - New Castle News
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Business Wire
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 - Yahoo Finance
Agenus Company Profile & Introduction - moomoo.com
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Agenus to Participate in Upcoming September Investor Conferences - Business Wire
Agenus to Participate in Upcoming September Investor Conferences - Yahoo Finance
Immigrant Entrepreneur Garo H. Armen Of Agenus Inc. Riccardo Braschi (I0EURkuuPl) - Mshale
New Phase 2 NEST Results Support Neoadjuvant BOT+BAL in Colon Cancer – Agenus - Oncodaily
Agenus reports survival data for colorectal cancer treatment By Investing.com - Investing.com South Africa
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism - Yahoo Finance
Agenus reports survival data for colorectal cancer treatment - investing.com
Agenus Inc: Shareholders Revolt Over Executive Pay! My Thoughts. Tampa Bay Rays (VzxHMd1TNP) - Mshale
Agenus Inc.AGEN Stock Chart Technical Analysis For 09-21-2020 Sporting Cp (0os72ROBex) - Mshale
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer - Yahoo Finance
Agenus Reports No Recurrences and Deep Pathologic Responses With Neoadjuvant BOT+BAL in Resectable Colon Cancer - Oncodaily
🔴 Agenus Inc. AGEN Stock Trading Facts 🔴 Gianna Nannini (9cYwfB9Crl) - Mshale
Agenus | Learn How I Turned $15,253 Into $1,613,442 Trading Biotech Stocks Donald Gibb (Gf1su3sDdD) - Mshale
4.22%
자본화:
|
볼륨(24시간):